JP2008528671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528671A5 JP2008528671A5 JP2007553700A JP2007553700A JP2008528671A5 JP 2008528671 A5 JP2008528671 A5 JP 2008528671A5 JP 2007553700 A JP2007553700 A JP 2007553700A JP 2007553700 A JP2007553700 A JP 2007553700A JP 2008528671 A5 JP2008528671 A5 JP 2008528671A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- use according
- histone deacetylase
- deacetylase inhibitor
- treatment comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 24
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 24
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229940110282 alimta Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- 229940120982 tarceva Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N ONC(/C=C/c1cc(S(Nc2ccccc2)(=O)=O)ccc1)=O Chemical compound ONC(/C=C/c1cc(S(Nc2ccccc2)(=O)=O)ccc1)=O NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64999105P | 2005-02-03 | 2005-02-03 | |
| US60/649,991 | 2005-02-03 | ||
| US73566205P | 2005-11-10 | 2005-11-10 | |
| US60/735,662 | 2005-11-10 | ||
| PCT/GB2006/000391 WO2006082428A2 (en) | 2005-02-03 | 2006-02-03 | Combination therapies using hdac inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012031556A Division JP5640026B2 (ja) | 2005-02-03 | 2012-02-16 | Ｈｄａｃ阻害剤を用いる併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008528671A JP2008528671A (ja) | 2008-07-31 |
| JP2008528671A5 true JP2008528671A5 (enExample) | 2012-04-19 |
| JP5156392B2 JP5156392B2 (ja) | 2013-03-06 |
Family
ID=36178242
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553700A Expired - Fee Related JP5156392B2 (ja) | 2005-02-03 | 2006-02-03 | Ｈｄａｃ阻害剤を用いる併用療法 |
| JP2012031556A Expired - Fee Related JP5640026B2 (ja) | 2005-02-03 | 2012-02-16 | Ｈｄａｃ阻害剤を用いる併用療法 |
| JP2014026011A Pending JP2014111642A (ja) | 2005-02-03 | 2014-02-14 | Ｈｄａｃ阻害剤を用いる併用療法 |
| JP2015081543A Pending JP2015147794A (ja) | 2005-02-03 | 2015-04-13 | Ｈｄａｃ阻害剤を用いる併用療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012031556A Expired - Fee Related JP5640026B2 (ja) | 2005-02-03 | 2012-02-16 | Ｈｄａｃ阻害剤を用いる併用療法 |
| JP2014026011A Pending JP2014111642A (ja) | 2005-02-03 | 2014-02-14 | Ｈｄａｃ阻害剤を用いる併用療法 |
| JP2015081543A Pending JP2015147794A (ja) | 2005-02-03 | 2015-04-13 | Ｈｄａｃ阻害剤を用いる併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20080213399A1 (enExample) |
| EP (7) | EP2946810A1 (enExample) |
| JP (4) | JP5156392B2 (enExample) |
| AU (1) | AU2006210746B2 (enExample) |
| CA (1) | CA2596210C (enExample) |
| NZ (2) | NZ599464A (enExample) |
| WO (1) | WO2006082428A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070020A2 (en) | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| EP2527460B1 (en) | 2004-05-27 | 2014-12-24 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| EP2946810A1 (en) | 2005-02-03 | 2015-11-25 | TopoTarget UK Limited | Combination therapy using an HDAC inhibitor and Vincristine for treating cancer |
| KR20080003334A (ko) * | 2005-03-11 | 2008-01-07 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제 |
| CN102579417B (zh) | 2005-05-13 | 2014-11-26 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| AU2006311820A1 (en) * | 2005-11-04 | 2007-05-18 | Merck Sharp & Dohme Corp. | Methods of using SAHA and erlotinib for treating cancer |
| EP2361619A1 (en) * | 2005-11-10 | 2011-08-31 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| EP2061758A4 (en) | 2006-09-11 | 2011-11-30 | Curis Inc | A ZINC BINDING GROUP CONTAINING SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS |
| EP2061469B8 (en) | 2006-09-11 | 2014-02-26 | Curis, Inc. | Quinazoline based egfr inhibitors |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| CA2662580C (en) | 2006-09-11 | 2013-05-21 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US8604044B2 (en) | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| CN101641338A (zh) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | 作为抗增殖制剂的多功能小分子 |
| US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
| CA2726734C (en) * | 2007-06-06 | 2014-10-07 | University Of Maryland, Baltimore | Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| JP5474792B2 (ja) | 2007-09-10 | 2014-04-16 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 |
| US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| CA2700173C (en) | 2007-09-25 | 2016-10-11 | Topotarget Uk Limited | Methods of synthesis of certain hydroxamic acid compounds |
| WO2009067543A2 (en) * | 2007-11-19 | 2009-05-28 | The Regents Of The University Of Colorado | Treatment of histone deacetylase mediated disorders |
| WO2009109861A1 (en) * | 2008-03-07 | 2009-09-11 | Topotarget A/S | Methods of treatment employing prolonged continuous infusion of belinostat |
| EP2385832B1 (en) | 2009-01-08 | 2015-07-15 | Curis, Inc. | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| GB0900555D0 (en) | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| AU2009348848B2 (en) * | 2009-06-26 | 2012-10-25 | Sunny Pharmtech, Inc. | Method for treating or ameliorating mucocutaneous or ocular toxicities |
| US20140314788A1 (en) * | 2010-04-09 | 2014-10-23 | Salk Institute For Biological Studies | Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto |
| MY166014A (en) * | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| DK3111938T3 (da) | 2011-04-01 | 2019-07-01 | Curis Inc | Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe |
| GB201217439D0 (en) * | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11998546B2 (en) | 2016-10-28 | 2024-06-04 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof |
| WO2018186032A1 (ja) | 2017-04-05 | 2018-10-11 | 国立大学法人千葉大学 | Ｓｗｉ／ｓｎｆ複合体の機能阻害剤 |
| US20190046513A1 (en) * | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| JP7467423B2 (ja) | 2018-09-11 | 2024-04-15 | キュリス，インコーポレイテッド | 亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法 |
| US20230008508A1 (en) * | 2019-12-10 | 2023-01-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapies for the treatment of cancer |
| EP4366716A4 (en) | 2021-07-08 | 2024-10-23 | Klotho Therapeutics, Inc. | NEW METHODS OF COMBINATORIAL ANTITUMOR TREATMENT AND RELATED COMPOSITIONS, KITS AND SYSTEMS |
| TR2022016254A1 (tr) * | 2022-10-26 | 2024-05-21 | Bi̇leci̇k Şeyh Edebali̇ Üni̇versi̇tesi̇ | Üçlü negatif meme kanseri tedavisi için bir kombine ilaç. |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| US6071923A (en) * | 1994-09-16 | 2000-06-06 | Bar-Ilan University | Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| PT923941E (pt) * | 1996-06-27 | 2006-09-29 | Chugai Pharmaceutical Co Ltd | Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| TR200101049T2 (tr) * | 1998-10-13 | 2002-01-21 | Fujisawa Pharmaceutical Co. Ltd. | Siklik tetrapeptid bileşiği ve kullanımı |
| US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US6316435B2 (en) * | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
| IL145941A (en) * | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US7105560B1 (en) * | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
| CA2391952C (en) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2002026696A1 (en) * | 2000-09-29 | 2002-04-04 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| JP4975941B2 (ja) | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途 |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| ES2310213T3 (es) | 2001-05-02 | 2009-01-01 | The Regents Of The University Of California | Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa. |
| CA2450129A1 (en) * | 2001-06-14 | 2002-12-27 | Donald G. Jackson | Novel human histone deacetylases |
| NZ531153A (en) | 2001-08-09 | 2005-10-28 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| DK1426054T3 (da) | 2001-08-21 | 2011-12-12 | Astellas Pharma Inc | Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| US20040191218A1 (en) * | 2001-09-26 | 2004-09-30 | Emlen James W | Pharmaceutical compositions and methods for treating cancer |
| CA2468312A1 (en) * | 2001-11-28 | 2003-06-05 | Dnaprint Genomics, Inc. | Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness |
| MXPA04006717A (es) | 2002-01-11 | 2004-11-10 | Matthias Rath | Una formulacion farmaceutica nutriente que comprende polifenoles y su uso para el tratamiento del cancer. |
| WO2003066889A2 (en) | 2002-02-07 | 2003-08-14 | Axys Pharmaceuticals, Inc. | Assay for acytyltransferase or deacetylase activity |
| US20050288227A1 (en) | 2002-02-15 | 2005-12-29 | Marks Paul A | Use of thioredoxin measurements for diagnostics and treatments |
| EP1482962A4 (en) | 2002-02-15 | 2009-12-23 | Sloan Kettering Inst Cancer | METHOD FOR THE TREATMENT OF TRX-MEDIATED ILLNESSES |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US20070060614A1 (en) | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| NZ550185A (en) | 2002-03-04 | 2008-10-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation Methods of inducing terminal differentiation |
| AU2003218737B2 (en) * | 2002-03-13 | 2008-04-10 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
| WO2003082286A1 (en) | 2002-04-03 | 2003-10-09 | Chemon Inc. | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| AU2003219595A1 (en) | 2002-04-11 | 2003-10-27 | In2Gen Co., Ltd. | Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS |
| WO2003088954A1 (en) * | 2002-04-15 | 2003-10-30 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
| US8883148B2 (en) | 2002-04-26 | 2014-11-11 | Asan Laboratories Company (Cayman), Limited | Prevention of joint destruction |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| EP1523318A4 (en) * | 2002-06-24 | 2007-07-04 | Res Dev Foundation | TREATMENT OF HUMAN MULTIPLE MYELOMA BY CURCUMIN |
| DE10233412A1 (de) | 2002-07-23 | 2004-02-12 | 4Sc Ag | Neue Verbindungen als Histondeacetylase-Inhibitoren |
| JP2005539001A (ja) | 2002-08-02 | 2005-12-22 | アージェンタ・ディスカバリー・リミテッド | ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸 |
| US20080004311A1 (en) | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| ITMI20030025A1 (it) | 2003-01-10 | 2004-07-11 | Italfarmaco Spa | Derivati dell'acido idrossammico ad attivita' antinfiammatoria. |
| TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| WO2004064727A2 (en) * | 2003-01-16 | 2004-08-05 | Georgetown University | Method of cancer treatment using hdac inhibitors |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| AU2003900608A0 (en) | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| EP1597390A4 (en) * | 2003-02-18 | 2006-12-27 | Maxcyte Inc | LOADING CELLS WITH ANTIGENES BY ELECTROPORATION |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| TW200424187A (en) | 2003-04-04 | 2004-11-16 | Hoffmann La Roche | New oxime derivatives and their use as pharmaceutically active agents |
| PL1611088T3 (pl) | 2003-04-07 | 2009-11-30 | Pharmacyclics Inc | Hydroksamiany jako środki terapeutyczne |
| US20040220242A1 (en) | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
| KR101351122B1 (ko) | 2003-05-09 | 2014-01-14 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| MXPA05012464A (es) * | 2003-05-21 | 2006-01-30 | Novartis Ag | Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos. |
| EP1491188A1 (en) | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| EP1663194B1 (en) | 2003-08-26 | 2010-03-31 | Merck HDAC Research, LLC | Use of SAHA for treating mesothelioma |
| JP2007504131A (ja) | 2003-08-29 | 2007-03-01 | エートン ファーマ インコーポレーティッド | 癌の組み合わせ処置法 |
| CA2590257A1 (en) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| EP1689445B1 (de) | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| US20070009956A1 (en) | 2003-12-30 | 2007-01-11 | Council Of Scientific And Industrial Research | Arginine hydrochloride enhances chaperone-like activity of alpha crystallin |
| GB0401876D0 (en) | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| ATE437370T1 (de) | 2004-02-27 | 2009-08-15 | Us Gov Health & Human Serv | Pharmakodynamische tests mit durchflusszytometrie |
| DE602004014723D1 (de) | 2004-04-30 | 2008-08-14 | Desitin Arzneimittel Gmbh | Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung |
| EP2476427B1 (en) | 2004-08-02 | 2018-01-17 | Zenyth Operations PTY. Ltd. | A method of treating cancer comprising a VEGF-B antagonist |
| EP1787657A1 (en) | 2004-08-06 | 2007-05-23 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for psychoneurotic disease |
| JP4946861B2 (ja) | 2004-08-09 | 2012-06-06 | アステラス製薬株式会社 | ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物 |
| US8889742B2 (en) | 2004-11-30 | 2014-11-18 | The Trustees Of The University Of Pennsylvania | Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| WO2006070024A2 (de) | 2004-12-31 | 2006-07-06 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| CA2594477C (en) | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2946810A1 (en) | 2005-02-03 | 2015-11-25 | TopoTarget UK Limited | Combination therapy using an HDAC inhibitor and Vincristine for treating cancer |
| US20060229237A1 (en) | 2005-04-07 | 2006-10-12 | Yih-Lin Chung | Treatment of gastrointestinal distress |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| CN102579417B (zh) | 2005-05-13 | 2014-11-26 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| CA2619568A1 (en) | 2005-08-19 | 2007-03-01 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Topical formulations of histone deacetylase inhibitors and methods of using the same |
| EP1940767A2 (en) | 2005-09-07 | 2008-07-09 | Plexxikon, Inc. | Pparactive compounds |
| WO2007049262A1 (en) | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
| EP2361619A1 (en) | 2005-11-10 | 2011-08-31 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| AU2007217562A1 (en) | 2006-02-22 | 2007-08-30 | 4Sc Ag | Indolopyridines as EG5 kinesin modulators |
| NZ571357A (en) | 2006-02-22 | 2010-11-26 | 4Sc Ag | Indolopyridines as EG5 kinesin modulators |
| GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
| EP1839656A1 (en) | 2006-03-31 | 2007-10-03 | TopoTarget Germany AG | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
| JP2009536186A (ja) | 2006-05-08 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌処置のためのジアゾール誘導体の医薬組合せ |
| EP2040731A4 (en) | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| WO2008011603A2 (en) | 2006-07-20 | 2008-01-24 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
| US20080242648A1 (en) | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| US8796330B2 (en) | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| WO2008090534A1 (en) | 2007-01-26 | 2008-07-31 | Berand Limited | Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity |
| WO2008094319A2 (en) | 2007-02-01 | 2008-08-07 | The Board Of Regents Of The University Of Texas Sytem | Methods and compositions of trail-death receptor agonists/activators |
| US8012695B2 (en) | 2007-02-14 | 2011-09-06 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to promoter regulation by MUC1 and KLF proteins |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| CA2726734C (en) | 2007-06-06 | 2014-10-07 | University Of Maryland, Baltimore | Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer |
| US20090246198A1 (en) | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| US8637554B2 (en) | 2008-05-07 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
-
2006
- 2006-02-03 EP EP15156493.7A patent/EP2946810A1/en not_active Withdrawn
- 2006-02-03 WO PCT/GB2006/000391 patent/WO2006082428A2/en not_active Ceased
- 2006-02-03 NZ NZ599464A patent/NZ599464A/en not_active IP Right Cessation
- 2006-02-03 EP EP12157335A patent/EP2522396A1/en not_active Withdrawn
- 2006-02-03 EP EP12156537A patent/EP2522395A1/en not_active Withdrawn
- 2006-02-03 EP EP06709637A patent/EP1855760A2/en not_active Withdrawn
- 2006-02-03 EP EP12156545A patent/EP2502649A1/en not_active Withdrawn
- 2006-02-03 NZ NZ589276A patent/NZ589276A/en not_active IP Right Cessation
- 2006-02-03 CA CA2596210A patent/CA2596210C/en not_active Expired - Lifetime
- 2006-02-03 US US11/815,372 patent/US20080213399A1/en not_active Abandoned
- 2006-02-03 EP EP12157341A patent/EP2500063A1/en not_active Withdrawn
- 2006-02-03 AU AU2006210746A patent/AU2006210746B2/en not_active Ceased
- 2006-02-03 EP EP12157337A patent/EP2522397A1/en not_active Withdrawn
- 2006-02-03 JP JP2007553700A patent/JP5156392B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-16 JP JP2012031556A patent/JP5640026B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-14 JP JP2014026011A patent/JP2014111642A/ja active Pending
- 2014-11-26 US US14/554,261 patent/US10285959B2/en not_active Expired - Lifetime
-
2015
- 2015-04-13 JP JP2015081543A patent/JP2015147794A/ja active Pending
-
2019
- 2019-03-26 US US16/364,634 patent/US10799469B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2605335C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2009536191A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| EP3313410A1 (en) | Compositions and methods for inhibiting arginase activity | |
| JP2017525730A5 (enExample) | ||
| JP2011503111A5 (ja) | ４−ヨード−３−ニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる乳がんの治療 | |
| JP2020097577A5 (enExample) | ||
| ES2625492T3 (es) | Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico | |
| JP2017526662A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| JP2014512355A5 (enExample) | ||
| JP2008508287A5 (enExample) | ||
| CN104755455B (zh) | 可用于治疗癌症的巨大戟醇衍生化合物 | |
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| JP2009503110A5 (enExample) | ||
| TW200512198A (en) | 5-arylpyrimidines as anticancer agents | |
| JP2019513812A5 (enExample) | ||
| RU2007141398A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИЗОИНДОЛОВ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ АКТИВНОСТИ БЕЛКА-ШАПЕРОНА Hsp90 | |
| Shimoyama et al. | Type-oriented intraoperative and adjuvant chemotherapy and survival after curative resection of advanced gastric cancer | |
| JP2013523867A5 (enExample) | ||
| JP2008525493A5 (enExample) | ||
| JP5694782B2 (ja) | 肺癌、腺癌及び他の病状のための治療方法及び組成物 | |
| JP2009534449A5 (enExample) | ||
| TWI284643B (en) | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |